Bladder cancer is one of the most common urogenital malignant with a rising incidence rate all over the world. Non-muscle invasive bladder cancer (NMIBC) has the characteristics of high recurrence rate and easy progression after receiving transurethral tumor resection combined with intravesical chemotherapy. The intrinsic or/and acquired drug resistance is mainly causing this poor outcome. The continuing advances in metabolomics and single-cell mass spectrometry have been considered as the key to promoting clinical precision medicine. Urinary exfoliated tumor cells (UETCs) carry the first-hand biological information on the genesis and progression of primary bladder cancer. Therefore, we hypothesized that the establishment of a drug resistance monitoring system for bladder cancer with intravesical chemotherapy based on UETCs single-cell metabolomics technology has a broad application prospect.
Keywords: Drug-resistance; Metabolomics; Non-muscle invasive bladder cancer; Single-cell mass spectrometry; Urinary exfoliated tumor cells.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.